# An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Source: https://onco.cc/trials/nct05884255/  
OnCo record `nct05884255` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide in pancreatic ductal adenocarcinoma, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. is a phase 3 interventional study registered as NCT05884255 by Jiangsu HengRui Medicine Co., Ltd., with 220 participants planned, started 2023-07-06 and due to reach its primary completion in 2026-12. Interventions recorded: Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide and long-acting Octreotide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05884255
- Phase: 3
- Setting: Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT05884255: https://clinicaltrials.gov/study/NCT05884255

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct05884255.json